Allogene (ALLO) director receives new stock options and RSU awards

Rhea-AI Filing Summary

Allogene Therapeutics director Arie Belldegrun reported new equity awards and updated share holdings. On February 2, 2026, he was granted a stock option for 929,913 shares of common stock at an exercise price of $1.87 per share and an award of 263,033 restricted stock units (RSUs), both held directly.

Twenty-five percent of the option vests on February 2, 2027, with the balance vesting in 36 equal monthly installments. The RSUs vest in four equal annual installments starting February 2, 2026, subject to continued service. Indirect common stock holdings are reported in entities including Bellco Legacy Trust fbo Rebecka Belldegrun, Vida Ventures LLC, Vida Ventures III partnerships, and Bellco Legacy LLC, along with 2,236,816 common shares held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Belldegrun Arie

(Last) (First) (Middle)

210 EAST GRAND AVE

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Allogene Therapeutics, Inc. [ ALLO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								4,710,120	I	See footnote(1)
Common Stock								1,798,163	I	See footnote(2)
Common Stock								1,724,137	I	See footnote(3)
Common Stock								539,867	I	See footnote(4)
Common Stock								2,236,816	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy)	$1.87	02/02/2026		A		929,913		(5)	02/02/2036	Common Stock	929,913	$0	929,913	D
Restricted Stock Unit	(6)	02/02/2026		A		263,033		(6)	(6)	Common Stock	263,033	$0	263,033	D

Explanation of Responses:

1. The securities are held in the name of Bellco Legacy Trust fbo Rebecka Belldegrun, of which the reporting person's spouse is trustee and beneficiary

2. The securities are held by Vida Ventures LLC (Vida), of which VV Manager LLC is the manager. There porting person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the common shares held by Vida. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

3. The securities are held by Vida Ventures III, L.P. and Vida Ventures III-A, L.P. Vida Ventures GP III, LLC is the manager of Vida Ventures III, L.P. and Vida Ventures III-A, L.P. The reporting person is a Senior Managing Director of Vida Ventures GP III, LLC and may therefore be deemed to be the beneficial owner of the common shares held by Vida Ventures III, L.P. and Vida Ventures III-A, L.P. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

4. The securities are held in the name of Bellco Legacy LLC. Bellco Legacy LLC is owned and managed by trusts controlled by the reporting person and Rebecka Belldegrun.

5. 25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter.

6. Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period from February 2, 2026, subject to continued service through the vesting date.

Remarks:

	/s/Earl Douglas, Attorney-in-Fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Allogene (ALLO) disclose for Arie Belldegrun?

Allogene reported that director Arie Belldegrun received a stock option for 929,913 shares at $1.87 per share and 263,033 RSUs on February 2, 2026. The filing also updates his direct and indirect common stock holdings.

How do the new stock options for Allogene (ALLO) director vest?

The stock option for 929,913 shares vests with 25% of the shares on February 2, 2027. The remaining 75% then vest in 36 equal monthly installments thereafter, aligning vesting with ongoing service over several years.

What are the vesting terms of the 263,033 RSUs granted at Allogene (ALLO)?

The 263,033 RSUs each represent a right to receive one Allogene common share. They vest in four equal annual installments starting on February 2, 2026, subject to the director’s continued service through each vesting date.

How many Allogene (ALLO) shares are held directly by Arie Belldegrun?

The Form 4 shows 2,236,816 shares of Allogene common stock held with direct ownership. Additional common shares are reported as indirectly owned through various trusts, LLCs, and investment partnerships identified in the footnotes.

Which entities hold Allogene (ALLO) shares associated with Arie Belldegrun?

Indirect holdings are reported in Bellco Legacy Trust fbo Rebecka Belldegrun, Vida Ventures LLC, Vida Ventures III, L.P., Vida Ventures III-A, L.P., and Bellco Legacy LLC. The filing notes that beneficial ownership is disclaimed except for any pecuniary interest.

Does the Allogene (ALLO) Form 4 report any insider share sales?

The Form 4 describes grants of a stock option and RSUs and lists updated holdings, but does not report any transactions coded as dispositions (D) of common stock. The derivative awards are shown with acquisition code A at $0 per unit.